A PHASE I STUDY OF AZD9291 IN PATIENTS WITH EGFR-TKI-RESISTANT ADVANCED NSCLC - UPDATED PROGRESSION FREE SURVIVAL AND DURATION OF RESPONSE DATA

被引：2
|
作者：
Jaenne, P. A. [1 ]
Ahn, M. -J. [2 ]
Kim, D. -W. [3 ]
Kim, S. -W. [4 ]
Planchard, D. [5 ]
Ramalingam, S. S. [6 ]
Frewer, P. [7 ]
Cantarini, M. [8 ]
Ghiorghiu, S. [9 ]
Yang, J. C. -H. [10 ]
机构：
[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Internal Med,Hematol,Oncol, Seoul, South Korea
[3] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[5] Gustave Roussy, Dept Med Oncol & Translat Res, Thorac Unit, Villejuif, France
[6] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
[7] Astra Zeneca, ECD Biometr, Macclesfield, Cheshire, England
[8] Astra Zeneca, Global Med Dept, Oncol, Macclesfield, Cheshire, England
[9] Astra Zeneca, Global Med Dev, Luton, Herts, England
[10] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
10.1093/annonc/mdv128.5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA3
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
    Callahan, Margaret K.
    Kluger, Harriet
    Postow, Michael A.
    Segal, Neil H.
    Lesokhin, Alexander
    Atkins, Michael B.
    Kirkwood, John M.
    Krishnan, Suba
    Bhore, Rafia
    Horak, Christine
    Wolchok, Jedd D.
    Sznol, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04) : 391 - +
  • [22] A Phase I/II Study of TQ-B2450 plus Anlotinib in EGFR plus Advanced NSCLC Patients Failed to Prior EGFR TKI Therapies: Phase II Results Updates
    Shi, M.
    Chen, P.
    Cui, L.
    Yao, Y.
    Wang, J.
    Zhou, T.
    Feng, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S157 - S157
  • [23] Intracranial anti-tumor activity of lazertinib in patients with advanced NSCLC who progressed after prior EGFR TKI therapy: Data from a phase I/II study.
    Kim, Sang-We
    Ahn, Myung-Ju
    Han, Ji-Youn
    Lee, Ki Hyeong
    Cho, Eun Kyung
    Lee, Yun-Gyoo
    Kim, Dong-Wan
    Kim, Joo-Hang
    Lee, Jong-Seok
    Lee, Gyeong-Won
    Shim, Byoung Yong
    Kim, Jin-Soo
    Chun, Sang Hoon
    Lee, Sung Sook
    Min, Young Joo
    Shin, Sang Won
    Lee, Young Joo
    Lee, Dae Ho
    Lee, Hana
    Cho, Byoung Chul
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
    Lim, S. M.
    Cho, B. C.
    Han, J-Y.
    Kim, S-W.
    Lee, K. H.
    Nagasaka, M.
    Baisamut, T. R.
    Jo, A.
    Seah, E.
    Kim, C.
    Ou, S-H. I.
    ANNALS OF ONCOLOGY, 2023, 34 : S1704 - S1705
  • [25] Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study
    Yuqing Lou
    Jianlin Xu
    Yanwei Zhang
    Jun Lu
    Tianqing Chu
    Xueyan Zhang
    Huimin Wang
    Hua Zhong
    Wei Zhang
    Baohui Han
    Targeted Oncology, 2020, 15 : 175 - 184
  • [26] Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study
    Lou, Yuqing
    Xu, Jianlin
    Zhang, Yanwei
    Lu, Jun
    Chu, Tianqing
    Zhang, Xueyan
    Wang, Huimin
    Zhong, Hua
    Zhang, Wei
    Han, Baohui
    TARGETED ONCOLOGY, 2020, 15 (02) : 175 - 184
  • [27] A phase I study of TQ-B2450, a PD-L1 mAb, plus anlotinib in EGFR plus advanced NSCLC patients failed to prior EGFR TKI therapies
    Feng, J.
    Shi, M.
    Wang, L.
    Yu, S.
    Yan, F.
    Peng, W.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S779 - S779
  • [28] A phase I/IIa study of icotinib hydrochloride, a novel oral EGFR-TKI, to evaluate its safety, tolerance, and preliminary efficacy in advanced NSCLC patients in China
    Zhao, Q.
    Zhou, J.
    Shentu, J.
    Xu, N.
    Tan, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] A phase I/II study of TQ-B2450, a PD-L1 mAb, plus anlotinib in EGFR plus advanced NSCLC patients failed to prior EGFR TKI therapies.
    Shi, Meiqi
    Wang, Li
    Yu, Shaorong
    Yan, Fei
    Peng, Wei
    Feng, Jifeng
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] Evaluating progression-free survival of EGFR exon 20ins in patients with advanced non-small lung cancer receiving EGFR inhibitors: A real-world data study
    Kabbaha, Suad
    Dempsey, Sarah Carder
    Thorlund, Kristian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345